Medlogix Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 9.78 M
- Company Age 6 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
About Medlogix Pharma
Medlogix Pharma Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 September 2018 (Six years and four months 22 days old ). Its registered office is in Tiruvallur, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 9.78 M, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Medlogix Pharma Private Limited India is Gunasekaran Rajakumar as CEO. Krishnamoorthi Madhanagopal, Munusamysah Srinivasan, and Gunasekaran Rajakumar serve as directors at the Company.
Company Details
-
Location
Tiruvallur, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999TN2018PTC124792
-
Company No.
124792
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
21 Sep 2018
-
Date of AGM
21 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Medlogix Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Gunasekaran Rajakumar | Managing Director | 12-Dec-2024 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Krishnamoorthi Madhanagopal
|
Director | 21-Sep-2018 | Current |
|
Munusamysah Srinivasan
|
Director | 19-Jan-2020 | Current |
Financial Performance of Medlogix Pharma.
Medlogix Pharma Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medlogix Pharma?
In 2019, Medlogix Pharma had a promoter holding of 32.00% and a public holding of 68.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Genremedy Pharmaceuticals Private LimitedMunusamysah Srinivasan and Gunasekaran Rajakumar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Medlogix Pharma?
Unlock and access historical data on people associated with Medlogix Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medlogix Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medlogix Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
